MX2023000033A - Arimoclomol para tratar la enfermedad de gaucher. - Google Patents

Arimoclomol para tratar la enfermedad de gaucher.

Info

Publication number
MX2023000033A
MX2023000033A MX2023000033A MX2023000033A MX2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A MX 2023000033 A MX2023000033 A MX 2023000033A
Authority
MX
Mexico
Prior art keywords
arimoclomol
gaucher disease
treating gaucher
treating
carbox
Prior art date
Application number
MX2023000033A
Other languages
English (en)
Inventor
Thomas Kirkegaard Jensen
Linda Ingemann
Christine Í Dali
Hinsby Anders Mørkeberg
Cathrine Kolster Fog-Tønnesen
Original Assignee
Kempharm Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Denmark As filed Critical Kempharm Denmark As
Publication of MX2023000033A publication Critical patent/MX2023000033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un ingrediente farmacéutico activo que se selecciona a partir de cloruro de N-[2-hidroxi-3-(1-piperidinil)-propoxi]-piridin-1-óxido-3-carboxi midoilo, sus estereoisómeros y las sales de adición de ácido del mismo; específicamente arimoclomol, para ser utilizado en métodos para tratar la enfermedad de Gaucher (GD).
MX2023000033A 2020-06-24 2021-06-24 Arimoclomol para tratar la enfermedad de gaucher. MX2023000033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
MX2023000033A true MX2023000033A (es) 2023-04-10

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000033A MX2023000033A (es) 2020-06-24 2021-06-24 Arimoclomol para tratar la enfermedad de gaucher.

Country Status (11)

Country Link
US (1) US20230226036A1 (es)
EP (1) EP4171559A1 (es)
JP (1) JP2023531750A (es)
KR (1) KR20230035586A (es)
CN (1) CN116075305A (es)
AU (1) AU2021295437A1 (es)
BR (1) BR112022026396A2 (es)
CA (1) CA3183559A1 (es)
IL (1) IL299250A (es)
MX (1) MX2023000033A (es)
WO (1) WO2021260120A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
CA3004867C (en) * 2008-06-26 2020-09-15 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
NZ713967A (en) * 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
KR102638203B1 (ko) * 2014-09-15 2024-02-19 제브라 덴마크 에이/에스 아리모클로몰 제제
BR112018070653A2 (pt) * 2016-04-29 2019-02-05 Orphazyme As ingrediente farmacêutico ativo, e, composição
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
JP2023531750A (ja) 2023-07-25
AU2021295437A1 (en) 2023-02-02
CN116075305A (zh) 2023-05-05
WO2021260120A1 (en) 2021-12-30
US20230226036A1 (en) 2023-07-20
IL299250A (en) 2023-02-01
CA3183559A1 (en) 2021-12-30
EP4171559A1 (en) 2023-05-03
BR112022026396A2 (pt) 2023-03-14
KR20230035586A (ko) 2023-03-14

Similar Documents

Publication Publication Date Title
Bousquet et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber
Crash-2 Collaborators The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
ES2728967T3 (es) Composiciones farmacéuticas
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
RS82003A (en) Anthranilic acid amides, method for the production thereof, their use as antiarhythmia agents, and pharmaceutical preparations thereof
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
HK1063185A1 (en) Quinoline derivatives and their use as tyrosine kinase inhibitors
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
RU2007137115A (ru) Новые офтальмологические композиции и способы их применения
RU2012157328A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
BR112021023640A2 (pt) Compostos de derivado de 1,3,4-oxadiazol homoftalimida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
RU2009122281A (ru) Средство для лечения заболеваний в ветеринарии на основе соли фосфония
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2023000033A (es) Arimoclomol para tratar la enfermedad de gaucher.
CN102548551A (zh) 治疗hiv感染的n-羟基-苯甲酰胺衍生物
US20210299230A1 (en) Medicine for covid-19 and treatment
UA86782C2 (ru) Применение галоидного производного гидроксамовой кислоты в лечении нейродегенеративных заболеваний центральной нервной системы
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
CY1123717T1 (el) Αριμοκλομολη για την αγωγη διαταραχων που σχετιζονται με γλυκοκερεβροσιδαση